Claims for Patent: 10,613,091

Summary for Patent: 10,613,091

Title:	Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
Abstract:	Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
Inventor(s):	Nixon; Andrew B. (Durham, NC), Hurwitz; Herbert I. (Durham, NC), Pang; Herbert (Durham, NC), Starr; Mark D. (Durham, NC)
Assignee:	Duke University (Durham, NC)
Application Number:	15/868,541
Patent Claims:	1. A method of predicting responsiveness of cancer in a subject to a cancer therapy including a VEGF targeting agent comprising: obtaining a sample from the subject; measuring a protein expression level of VEGF-D in the sample from the subject, wherein measuring a protein expression level of VEGF-D of less than 1100 pg/mL is predictive of responsiveness to a VEGF targeting agent; and treating the subject with the VEGF targeting agent if the cancer is predicted to be responsive to the VEGF targeting agent. 2. The method of claim 1, wherein the subject is human. 3. The method of claim 2, wherein the subject is a human patient diagnosed with cancer or undergoing, or about to undergo, a cancer treatment regimen. 4. The method of claim 1, wherein the VEGF targeting agent is bevacizumab or gemcitabine. 5. The method of claim 1, wherein the cancer therapy includes a nucleotide analog or other inhibitor of DNA synthesis and repair. 6. The method of claim 1, wherein the cancer is pancreatic cancer. 7. The method of claim 1, wherein the sample is blood, plasma, serum, or urine. 8. The method of claim 1, wherein the protein expression level is determined by a method selected from ELISA, immunofluorescence; FACS analysis, Western blot, magnetic immunoassays, and antibody-based microarrays. 9. A method of treating cancer in a subject comprising: administering a VEGF targeting agent to the subject if a sample from the subject has a protein expression level of VEGF-D that is less than 1100 pg/mL. 10. The method of claim 9, wherein the sample is blood, plasma, serum, or urine. 11. The method of claim 9, wherein the protein expression level is determined by a method selected from the group consisting of ELISA, immunofluorescence, FACS analysis, Western blot, magnetic immunoassays, and antibody-based microarrays. 12. The method of claim 9, wherein the VEGF targeting agent is bevacizumab. 13. The method of claim 9, wherein the cancer is pancreatic cancer.

Details for Patent 10,613,091

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-05-05